Previous 10 | Next 10 |
2024-03-21 20:22:02 ET Journey Medical Corporation (DERM) Q4 2023 Earnings Conference Call March 21, 2024 04:30 PM ET Company Participants Jaclyn Jaffe - Senior Director, Corporate Operations Claude Maraoui - Co-Founder, President and CEO Joseph Benesch - Interim...
2024-03-21 16:04:13 ET More on Journey Medical Journey Medical announces U.S. FDA acceptance of NDA for its rosacea treatment Journey Medical submits NDA for DFD-29 for rosacea Seeking Alpha’s Quant Rating on Journey Medical Historical earnings data fo...
Company generated total revenues of $79.2 million for the full year ended December 31, 2023, a 7% increase from the $73.7 million reported in 2022 Achieved $15.6 million in operating cost savings in 2023, ahead of initial guidance of $...
X4 Pharmaceuticals Inc. (XFOR) is expected to report $-0.15 for Q4 2023 Li Ning Co., Ltd. ADR (LNNGY) is expected to report for Q4 2023 Xos Inc. (XOS) is expected to report $-2.4 for Q4 2023 PainReform Ltd. (PRFX) is expected to report for quarter end 2023-12-31 Muenchener Rueckve...
2024-03-20 17:35:53 ET More on Journey Medical Journey Medical announces U.S. FDA acceptance of NDA for its rosacea treatment Journey Medical submits NDA for DFD-29 for rosacea Seeking Alpha’s Quant Rating on Journey Medical Historical earnings data fo...
2024-03-20 17:35:09 ET Major earnings expected after the bell on Thursday include: NIKE ( NKE ) FedEx Corporation ( FDX ) Lululemon Athletica ( LULU ) Asensus Surgical ( ASXC ) AAR Corp. ( AIR ) Read the full article on Seeking Alpha F...
2024-03-18 09:17:32 ET More on Journey Medical Journey Medical submits NDA for DFD-29 for rosacea Journey Medical secures credit facility for up to $20M Seeking Alpha’s Quant Rating on Journey Medical Historical earnings data for Journey Medical ...
SCOTTSDALE, Ariz., March 18, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (...
SCOTTSDALE, Ariz., March 15, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that focuses on the selling and marketing of FDA-approved prescription pharmaceutical produc...
SCOTTSDALE, Ariz., March 13, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment ...
News, Short Squeeze, Breakout and More Instantly...
Journey Medical Corporation Company Name:
DERM Stock Symbol:
NASDAQ Market:
Journey Medical Corporation Website:
DALLAS, TX / ACCESSWIRE / July 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small and mid-sized commercial-stage companies, today provided a corporate progress update as well as a summary of the achieve...
SCOTTSDALE, Ariz., July 11, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescriptio...
Journey Medical Corporation (NASDAQ: DERM) is the focus of IBN's latest stock spotlight. The company's shares have moved -1.78% on the day to $5.51. Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological condi...